Citations

Clear

2429 citation(s) found for "Shah, SS".

ProtPipe: A Multifunctional Data Analysis Pipeline for Proteomics and Peptidomics
Li, Ziyi , Weller, Cory A. , Shah, Syed Islamuddin , Johnson, Nicholas L. , Hao, Ying , Roberts, Jessica P. , Guha, Deyaan, Bereda, Colleen , Klaisner, Sydney, Machado, Pedro , Zanovello, Matteo , Prudencio, Mercedes , Staff, Nathan P. , Fratta, Pietro , Petrucelli, Leonard , Cookson, Mark , Ward, Michael E. , Singleton, Andrew , Nalls, Mike A. , Fratta, Pietro , Shah, Syed I , Jarreau, Paige B , Roberts, Jessica , Guha, Deyaan , Bereda, Colleen , Klaisner, Sydney , Machado, Pedro M , Zanovello, Matteo , Prudencio, Mercedes , Oskarsson, Björn , Staff, Nathan P , Dickson, Dennis W , Fratta, Pietro , Petrucelli, Leonard , Narayan, Priyanka , Ward, Michael E , Singleton, Andrew B , Nalls, Mike A , Qi, Yue A , Li, Ziyi , Fratta, Pietro , Johnson, Nicholas L , Oskarsson, Björn , Dickson, Dennis W. , Qi, Yue

Mayo Clinic

Genomics, Proteomics & Bioinformatics | November 22, 2024 | Volume: 22 | Issue: 6 | Pages: No page available

10.1093/gpbjnl/qzae083 | PMID 39576693 Get It

Abstract Mass spectrometry (MS) is a technique widely employed for the identification and characterization of proteins, with personalized medicine, systems biology, and biomedical applications. The application of MS-based proteomics advances our understanding of protein function, cellular signaling, and complex biological systems. MS data analysis is a critical process that includes identifying and quantifying proteins and peptides and then exploring their biological functions in downstream analyses. To address the complexities associated with MS data analysis, we developed ProtPipe to streamline and automate the processing and analysis of high-throughput proteomics and peptidomics datasets with DIA-NN preinstalled. The pipeline facilitates data quality control, sample filtering, and normalization, ensuring robust and reliable downstream analyses. ProtPipe provides downstream analyses, including protein and peptide differential abundance identification, pathway enrichment analysis, protein–protein interaction analysis, and major histocompatibility complex (MHC)–peptide binding affinity analysis. ProtPipe generates annotated tables and visualizations by performing statistical post-processing and calculating fold changes between predefined pairwise conditions in an experimental design. It is an open-source, well-documented tool available at https://github.com/NIH-CARD/ProtPipe, with a user-friendly web interface.
Moving beyond tokenism: Sustaining engagement of persons living with dementia in identifying emergency research priorities
Sandoval, Jacqueline , Carpenter, Christopher R. , Shah, Manish N. , Dussetschleger, Jeffrey, Gil, Heidi, Jaspal, Naveena, Jobe, Deborah, Vann, Allan, Webb, Teresa, Hwang, Ula , Carpenter, Christopher R , Shah, Manish N , Hwang, Ula , Gilmore‐Bykovskyi, Andrea L , Dresden, Scott M. , Ellenbogen, Michael I.

Mayo Clinic

Journal of the American Geriatrics Society | November 22, 2024 | Volume: 73 | Issue: 5 | Pages: 1344-1352

10.1111/jgs.19269 | PMID 39576051 Get It

Abstract Introduction The Geriatric Emergency Care Applied Research Network 2.0‐Advancing Dementia Care (GEAR 2.0‐ADC) aims to advance research efforts to improve the emergency care of persons living with dementia (PLWDs). Objective To support this objective, GEAR 2.0‐ADC convened a virtual consensus conference to prioritize emergency care research opportunities for PLWDs inclusive of perspectives of PLWDs to ensure identification of research gaps in response to their experiences and priorities. Inclusion of PLWDs as research partners is increasingly recognized as a best practice, however, approaches to facilitating consensus participation are lacking. Methods Best practices for supporting the engagement of PLWDs in a consensus conference, applied across its three phases (pre‐conference, during the conference, and post‐conference), include: establishing a learning environment focused on research priorities before the event, presenting information in ways that align with participants' learning preferences while accommodating cognitive impairments, and providing multiple opportunities and methods for gathering post‐conference feedback from PLWDs. Results These strategies were identified by PLWDs and care partners (CPs) through semi‐structured interviews, who were involved in the convening process, aimed at exploring ways to enhance facilitation techniques for participants. Conclusion Additionally, these summarized insights aim to encourage the use of community‐engaged approaches in discussions and consensus‐building around research priorities in emergency care, particularly for PLWDs and their CPs.
QUEST-AI: A System for Question Generation, Verification, and Refinement using AI for USMLE-Style Exams
Bedi, Suhana , Morse, Keith , Kumar, A., Jindal, Jenelle , Davenport, Conor , Fleming, Scott L. , Chiang, Chia‐Chun , Patel, Birju , Yamaguchi, Craig , Shah, Nigam H.

Mayo Clinic

Biocomputing 2025 | November 22, 2024 | Volume: No volume available | Issue: No issue available | Pages: 54-69

10.1142/9789819807024_0005 | PMID 39670361 Get It

Association of left atrial function with vascular brain injury: The Atherosclerosis Risk in Communities study
Wang, Wendy , Lutsey, Pamela L. , Reyes, Jorge L. , Mosley, Thomas H. , Johansen, Michelle C. , Alonso, Álvaro , Jack, Clifford R. , Solomon, Scott D. , Shah, Amil, Wasserman, Bruce A. , Shah, Amil M. , Johansen, Michelle C , Jack, Clifford R , Alonso, Alvaro , Lutsey, Pamela L , Shah, Amil , Inciardi, Riccardo M. , Gottesman, Rebecca F. , Solomon, Scott David , Chen, Lin Y.

Mayo Clinic

European Journal of Neurology | November 21, 2024 | Volume: 32 | Issue: 1 | Pages: No page available

10.1111/ene.16549 | PMID 39569699 Get It

AbstractBackground and purposeLower left atrial (LA) function is associated with higher dementia risk and may be mechanistically linked through vascular brain injury, an established correlate for higher dementia risk. Using data from the Atherosclerosis Risk in Communities study, we assessed the cross‐sectional association between LA function and brain magnetic resonance imaging (MRI) markers of vascular brain injury.MethodsWe included 1488 participants who were free of prevalent dementia, stroke, or atrial fibrillation and who underwent a two‐dimensional echocardiogram and brain MRI in 2011–2013 (mean [± standard deviation] age 76 [± 5] years, 60% female, 27% Black). LA function measures (reservoir, conduit, contractile strain) were assessed in quartiles. Brain MRI measures included cerebral microbleeds, brain infarcts, and white matter hyperintensity (WMH) volume. Logistic regression was used for dichotomous outcomes. Linear regression was used for WMH volume.ResultsOverall, 343 (23%) and 344 participants (23%) had ≥1 cerebral microbleed or brain infarct. After multivariable adjustments, the lowest LA reservoir and conduit strain quartiles (vs. highest quartile) were associated with higher odds of the presence of ≥1 cerebral microbleed (odds ratios [95% confidence intervals] 1.78 [1.42–2.22] and 1.52 [1.22–1.90]). Compared to the highest quartile, participants in the lowest LA conduit strain quartile had 1.51 (95% confidence interval 1.22–1.88) times higher odds of having ≥1 brain infarct. Lower LA contractile strain was associated with lower odds of brain infarcts. No association with WMH volume was noted.ConclusionsWe found that LA reservoir and conduit strain were associated with cerebral microbleeds and brain infarcts. Lower LA function may be linked to dementia risk via vascular brain injury. Prospective studies are needed to confirm these findings.
Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial
Judge, Daniel P. , Gillmore, Julian D. , Ambardekar, Amrut V. , Cappelli, Francesco , Fontana, Marianna , Grodin, Justin L. , Grogan, Martha , Hanna, Mazen, Masri, Ahmad , Nativi-Nicolau, José , Sarswat, Nitasha , Shah, Keyur, Cao, Xiaofan, Wang, Kevin , Tamby, Jean‐François, Katz, Leonid , Sinha, Uma, Fox, Jonathan C. , Maurer, Mathew S. , Alexander, Kevin M , Ambardekar, Amrut V , Cappelli, Francesco , Fontana, Marianna , Garcia-Pavia, Pablo , Grodin, Justin L , Grogan, Martha , Masri, Ahmad , Nativi-Nicolau, Jose , Obici, Laura , Sarswat, Nitasha , Soman, Prem , Lystig, Ted , Fox, Jonathan C , Maurer, Mathew S , Gillmore, Julian D , Judge, Daniel P , Hanna, Mazen, Obici, Laura , Poulsen, Steen Hvitfeldt , Pecoraro, Maria Lucia

Mayo Clinic

Circulation | November 18, 2024 | Volume: 151 | Issue: 9 | Pages: 601-611

10.1161/circulationaha.124.072771 | PMID 39556242 Get It

BACKGROUND: In the phase 3 randomized controlled study ATTRibute-CM (Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy), acoramidis, a transthyretin stabilizer, demonstrated significant efficacy on the primary end point. Participants with transthyretin amyloid cardiomyopathy who completed ATTRibute-CM were invited to enroll in an open-label extension study (OLE). We report the efficacy and safety data of acoramidis in participants who completed ATTRibute-CM and enrolled in the ongoing OLE. METHODS: Participants who previously received acoramidis through month 30 in ATTRibute-CM continued to receive it (continuous acoramidis), and those who received placebo through month 30 were switched to acoramidis (placebo to acoramidis). Participants who received concomitant tafamidis in ATTRibute-CM were required to discontinue it to be eligible to enroll in the OLE. Clinical efficacy outcomes analyzed through month 42 included time to event for all-cause mortality (ACM) or first cardiovascular-related hospitalization (CVH), ACM alone, first CVH alone, ACM or recurrent CVH, change from baseline in NT-proBNP (N-terminal pro-B-type natriuretic peptide), 6-minute walk distance, serum transthyretin, and Kansas City Cardiomyopathy Questionnaire Overall Summary score. Safety outcomes were analyzed through month 42. RESULTS: Overall, 438 of 632 participants in ATTRibute-CM completed treatment, and 389 enrolled in the ongoing OLE (263 continuous acoramidis and 126 placebo to acoramidis). The hazard ratio for ACM or first CVH was 0.57 (95% CI, 0.46–0.72) at month 42 based on a stratified Cox proportional hazards model ( P <0.0001) favoring continuous acoramidis. Similar analyses were performed on ACM alone and first CVH alone, with hazard ratios of 0.64 (95% CI, 0.47–0.88) and 0.53 (95% CI, 0.41–0.69), respectively, at month 42. Treatment effects for NT-proBNP and 6-minute walk distance also favored continuous acoramidis. On initiation of open-label acoramidis in the placebo-to-acoramidis arm, there was a prompt increase in serum transthyretin. Quality of life assessed by Kansas City Cardiomyopathy Questionnaire Overall Summary score was well preserved in continuous-acoramidis participants compared with the placebo-to-acoramidis participants. No new clinically important safety issues were identified in this long-term evaluation. CONCLUSIONS: Early initiation and continuous use of acoramidis in the ATTRibute-CM study through month 42 of the ongoing OLE study were associated with sustained clinical benefits in a contemporary transthyretin amyloid cardiomyopathy cohort, with no clinically important safety issues newly identified. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04988386.
Heart Failure in Zero Gravity—External Constraint and Cardiac Hemodynamics
Hearon, Christopher M. , Manferdelli, Giorgio , Shah, Aman , Tayon, Kevin G. , Sarma, Satyam , Levine, Benjamin D., MacNamara, James P. , Pandey, Ambarish , Levine, Benjamin D.

Mayo Clinic

JAMA Cardiology | November 16, 2024 | Volume: 10 | Issue: 1 | Pages: 98

10.1001/jamacardio.2024.4596 | PMID 39549275 Get It

In this case series study, pulmonary artery systolic, diastolic, and mean pressures of 2 participants with obesity and heart failure with preserved ejection fraction were measured at zero gravity during parabolic flight to assess the effect of external constraint on left ventricular filling pressures.
Abstract 4147141: Relationship Between CVH and Survival in the Acoramidis Treated Participants Within ATTRibute-CM
Davis, Margot K. , Ambardekar, Amrut, Nativi-Nicolau, José , Shah, Keyur B. , Hanna, Mazen, Gibbs, Simon, Tamby, Jean‐François, Siddhanti, Suresh , Whang, John , Fox, Jonathan C. , Du, Jing, Cheng, Richard K. , Cheng, Richard , Alexander, Kevin M , Ambardekar, Amrut V. , Hanna, Mazen

Mayo Clinic

Circulation | November 14, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4147141 Get It

Background: Acoramidis is a novel, potent, investigational, transthyretin (TTR) stabilizer under development for the treatment of TTR amyloidosis that results in near-complete (≥90%) TTR stabilization. In a phase 3 study, ATTRibute-CM, acoramidis demonstrated improved clinical outcomes in participants with transthyretin amyloid cardiomyopathy (ATTR-CM), including a 50% reduction in the risk of CVH compared to placebo over 30 months. The study also demonstrated that cardiovascular hospitalization (CVH) during the study predicted a higher subsequent mortality in participants with ATTR-CM. Hypothesis: CVH portends a higher risk of mortality in participants with ATTR-CM. Since acoramidis reduces CVH, it can improve the prognosis of participants with ATTR-CM. Aim: To evaluate the relationship between CVH and survival in the acoramidis group within ATTRibute-CM. Methods: In this post-hoc analysis, the relationship between those with or without CVH and survival was analyzed within the acoramidis treatment group using the Kaplan-Meier (KM) estimator method. Results: Demographics and baseline disease characteristics were mostly comparable between acoramidis-treated participants with and without CVH, although participants with CVH had a higher baseline NT-proBNP and lower eGFR. At Month 30, in acoramidis-treated participants, those without any CVH (n=300) had a higher survival [86.8% (95% CI = 82.2, 90.3)] versus 62.4% (95% CI = 52.6, 70.7) in those who had any CVH (n=109); p<0.0001 from log-rank test (Figure). Conclusion: In the ATTRibute-CM study, pts without any CVH receiving acoramidis have a higher survival rate. CVHs remain a powerful predictor of mortality. This reinforces the importance of an effective therapy that reduces CVH and in turn may improve survival in patients with ATTR-CM.
Abstract 4147050: Genetic Insights into Arrhythmogenic Mitral Valve Prolapse – A Case-Control Study from UK Biobank and NIH All of Us
Dabbagh, Ghaith Sharaf , Hesse, Kerrick , Agnihotri, Ruchi, Kaur, Gurpreet , Gurumoorthi, Manasa, Mitchell, Saige M. , Pargament, Robert, Malik, Adnan , Schuler, Brian, Obeng‐Gyimah, Edmond, Ricci, Fabrizio , Landstrom, Andrew P. , Landstrom, Andrew P , Agnihotri, Ruchi, Shah, Ravi V. , Asatryan, Babken , Galanti, Kristian , Wolfe, Rachel, Malik, Adnan, Munroe, Patricia B. , Somers, Virend K. , Ricci, Fabrizio , Khanji, Mohammed Y , Chahal, C. Anwar A.

Mayo Clinic

Circulation | November 14, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4147050 Get It

Background: Mitral valve prolapse (MVP) is a common valvular abnormality. Observational studies demonstrate an association between MVP and increased risk of sudden cardiac death from ventricular arrhythmias, coined arrhythmogenic MVP. A genetic component has been postulated but remains under-investigated. Hypothesis: Predicted deleterious variants in Mendelian cardiomyopathy and arrhythmia genes are more frequent in arrhythmogenic MVP (aMVP) compared to non-arrhythmogenic MVP. Aims: To comprehensively phenotype and genotype a single-center aMVP cohort and compare to non-aMVP from two large population-based cohorts and investigate their clinical outcomes. Methods: The aMVP cohort included 46 prospectively enrolled patients from a regional referral center for inherited cardiovascular disease and had undergone multi-modality imaging and clinical gene panel testing. The non-aMVP comparator cohorts included 453 participants from the UK Biobank (UKBB), a prospective cohort of 500,000 UK residents, and 1,418 participants from the National Institutes of Health (NIH) All of Us (AoU), a prospective cohort of 450,000 USA participants. Gene variants were annotated in ANNOVAR. Participants with and without pathogenic/likely pathogenic (P/LP) variants reported on ClinVar with ≥2-star level of evidence were considered genotype positive (G+) and negative (G-) respectively. Results: The demographics for aMVP (age 61.2 ± 12.8 years, 56.5% female) and non-aMVP (UKBB: age 59.8 ± 7.3 years, 50.7% female and AoU: age 65.3 ± 13.4 years, 76.2% female) were comparable. G+ participants were more prevalent in the aMVP cohort 10/46 (21.7%) versus non-aMVP in the UKBB 8/453 (1.8%) and in the AoU 21/1418 (1.5%); p<0.001. The most frequently implicated gene in aMVP was TTN . Of 46 in aMVP cohort, 33 (71%) underwent CMR. G+ participants had a higher frequency of late gadolinium enhancement [6/6 (100%) vs. 14/27 (51.8%), p<0.001] and wall motion abnormalities [3/6 (50%) vs. 1/27 (3.7%), p<0.001] compared to G- participants. The aMVP cohort had significantly more implantable cardioverter defibrillator (ICD) implants compared to non-aMVP cohort [5/46 (10.9%) vs. 1/453 in UKBB (0.2%), p<0.001]. G+ aMVP cohort showed a trend for developing heart failure and ICD implants compared to G- aMVP . Conclusion: P/LP variants in cardiomyopathy and arrhythmia genes are more prevalent in aMVP participants compared to non-aMVP participants. This could be a hitherto unrecognized effect modifier predicting aMVP .
Abstract 4145340: Health System Variability in Lipid Management for Patients with Atherosclerotic Cardiovascular Disease: An Analysis from Cv-MOBIUS
Shrader, Peter, Shoji, Satoshi , Fernández, Soledad, Arnold, Jonathan , Allred, Clint, Priest, Elisa L. , Syed, Mahanaz, Kirchner, H. Lester , Leja, Monika, Ahmad, Zahid , Kalich, Bethany , Fernandez, Soledad , Shah, Nishant , Martin, Seth S. , Chamberlain, Alanna M. , Shapiro, Michael D. , Effron, Mark B , Chrischilles, Elizabeth A. , Dhalwani, Nafeesa N , Jones, Laney K , Wojcik, Cezary , Peterson, Eric D. , Návar, Ann Marie

Mayo Clinic

Circulation | November 14, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4145340 Get It

Background: Nationally, many ASCVD patients fail to achieve an LDL-C <70 mg/dL, and uptake of both statin and non-statin therapies is low. The degree to which this varies across health systems is less clear. Methods: A cross sectional analysis was performed where lipid levels and lipid lowering therapies (LLT) were assessed using electronic health record data in patients with a previous diagnosis of ASCVD. The data was obtained across 14 US healthcare systems between 1/1/2021-12/31/2022. Proportions of patients with an active prescription of any statin, high intensity statin, ezetimibe, PCSK9i, and combination therapy (two or more agents) within 395 days of the most recent LDL-C value (index date) was evaluated overall and by participating site. Additionally, the proportion of patients with an LDL-C <70 mg/dL at the index date was also assessed. Results: Across 14 health systems, 1,118,623 patients with ASCVD were identified (median 61,840 per health system, range 8,161-182,315). Overall, 675,776 (60.4%) had an LDL-C level in the past year (range 39.1% - 70.8%). Of those with a lipid level, achievement of LDL-C <70 mg/dL ranged from 34.6-47.2%. In total, 42.6% were on any statin, 20.1% were on a high intensity statin, 4.3% on ezetimibe, and 1.2% on a PCSK9i. Only 2.9% were on combination therapy of a statin with ezetimibe or a PCSK9i. Variability was seen across health systems in utilization of each of these therapies, however even in the highest performing health systems, LLT uptake and achievement of LDL-C < 70mg/dL remained low ( Figure). Conclusion: Variability in utilization of LLT in ASCVD patients between health systems suggests that system-level factors may impact achieving guideline-based LDL-C goals. Despite the variability, the highest proportion of patients achieving an LDL-C <70mg/dL remained under 50% indicating the need for aggressive implementation efforts.